Show simple item record

dc.contributor.authorZambonelli, Carlo
dc.contributor.authorDey, Antu K.
dc.contributor.authorHilt, Susan
dc.contributor.authorStephenson, Samuel
dc.contributor.authorGo, Eden P.
dc.contributor.authorClark, Daniel Forrest
dc.contributor.authorWininger, Mark
dc.contributor.authorLaBranche, Celia
dc.contributor.authorMontefiori, David C.
dc.contributor.authorLiao, Hua-Xin
dc.contributor.authorSwanstrom, Ronald I.
dc.contributor.authorDesaire, Heather
dc.contributor.authorHaynes, Barton F.
dc.contributor.authorCarfi, Andrea
dc.contributor.authorBarnett, Susan W.
dc.date.accessioned2017-11-03T20:19:43Z
dc.date.available2017-11-03T20:19:43Z
dc.date.issued2016-07-21
dc.identifier.citationZambonelli, C., Dey, A. K., Hilt, S., Stephenson, S., Go, E. P., Clark, D. F., … Barnett, S. W. (2016). Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. PLoS ONE, 11(7), e0157391. http://doi.org/10.1371/journal.pone.0157391en_US
dc.identifier.urihttp://hdl.handle.net/1808/25261
dc.description.abstractThe viral envelope glycoprotein (Env) is the major target for antibody (Ab)-mediated vaccine development against the Human Immunodeficiency Virus type 1 (HIV-1). Although several recombinant Env antigens have been evaluated in clinical trials, only the surface glycoprotein, gp120, (from HIV-1 subtype B, MN, and subtype CRF_01AE, A244) used in the ALVAC prime-AIDSVAX gp120 boost RV144 Phase III HIV vaccine trial was shown to contribute to protective efficacy, although modest and short-lived. Hence, for clinical trials in southern Africa, a bivalent protein boost of HIV-1 subtype C gp120 antigens composed of two complementary gp120s, from the TV1.C (chronic) and 1086.C (transmitted founder) HIV-1 strains, was selected. Stable Chinese Hamster Cell (CHO) cell lines expressing these gp120s were generated, scalable purification methods were developed, and a detailed analytical analysis of the purified proteins was conducted that showed differences and complementarity in the antigenicity, glycan occupancy, and glycan content of the two gp120 molecules. Moreover, mass spectrometry revealed some disulfide heterogeneity in the expressed proteins, particularly in V1V2-C1 region and most prominently in the TV1 gp120 dimers. These dimers not only lacked binding to certain key CD4 binding site (CD4bs) and V1V2 epitope-directed ligands but also elicited reduced Ab responses directed to those epitopes, in contrast to monomeric gp120, following immunization of rabbits. Both monomeric and dimeric gp120s elicited similarly high titer Tier 1 neutralizing Abs as measured in standard virus neutralization assays. These results provide support for clinical evaluations of bivalent preparations of purified monomeric TV1.C and 1086.C gp120 proteins.en_US
dc.publisherPublic Library of Scienceen_US
dc.rights© 2016 Zambonelli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleGeneration and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africaen_US
dc.typeArticleen_US
kusw.kuauthorGo, Eden P.
kusw.kuauthorClark, Daniel F.
kusw.kuauthorDesaire, Heather
kusw.kudepartmentChemistryen_US
dc.identifier.doi10.1371/journal.pone.0157391en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC4956256en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2016 Zambonelli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Except where otherwise noted, this item's license is described as: © 2016 Zambonelli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.